ML
MLTX.US MoonLake Immunotherapeutics
- Market cap
- USD 1.06B
- P/E
- -
- P/B
- 2.79x
- ROE
- -73.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is MLTX.US undervalued?
Graham numberThe Graham number of MoonLake Immunotherapeutics cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MoonLake Immunotherapeutics fundamental analysis
No fundamental analysis for MoonLake Immunotherapeutics yet.
MoonLake Immunotherapeutics stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquarte…
Full company profileMoonLake Immunotherapeutics financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
MoonLake Immunotherapeutics annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | -4.97K | -12.4K | -13.2K | -1.38M | -2.62M | - |
| Operating Income | -106K | -4.57M | -65.1M | -54.1M | -143M | -245M | -282M |
| EBITDA | -90.8K | -4.57M | -65.0M | -43.6M | -120M | -220M | -266M |
| Net Income | -90.8K | -4.54M | -64.5M | -36.0M | -119M | -227M | -281M |
| EPS | -0.01 | -0.12 | -2.20 | -0.73 | -1.89 | -3.53 | -3.30 |
| Balance Sheet | |||||||
| Total Assets | 117M | 9.68M | 76.8M | 527M | 478M | 424M | 541M |
| Total Liabilities | 4.15M | 21.3M | 8.08M | 13.0M | 24.5M | 120M | 159M |
| Shareholders' Equity | 112M | -11.6M | 48.9M | 496M | 447M | 304M | 382M |
| Cash & Short-term Investments | 1.34M | 8.04M | 72.1M | 511M | 448M | 394M | 498M |
| Total Debt | 58.1K | 15.0M | 283K | 3.70M | 2.83M | 75.7M | 102M |
| Cash Flow | |||||||
| Operating Cash Flow | -317K | -35.2M | -55.9M | -42.8M | -117M | -196M | -247M |
| Capital Expenditure | 0.00 | 50.7K | 16.0K | 284K | 520K | 35.0K | 0.00 |
| Free Cash Flow | -317K | -35.2M | -55.9M | -43.1M | -117M | -196M | -247M |
| Ratios | |||||||
| ROE | -0.1% | - | -131.9% | -7.3% | -26.6% | -74.7% | -73.7% |
| ROA | -0.1% | -46.9% | -83.9% | -6.8% | -24.9% | -53.6% | -52.0% |
| Debt to Equity | 0.00x | - | 0.01x | 0.01x | 0.01x | 0.25x | 0.27x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
MoonLake Immunotherapeutics dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | USD 51.9K | 0.00 | - |
| 2020 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns MoonLake Immunotherapeutics
- Insiders 8.62%
- Institutions 87.90%
- Public & others 3.49%
- Shares outstanding 85.1M
- Free float 55.5M
Top funds holding MLTX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| T. Rowe Price Small-Cap Value | 1.41M | 1.66% | +4.84% | Sep 2026 |
| abrdn Healthcare Investors | 819K | 0.96% | 0.00% | Oct 2026 |
| Janus Henderson Hrzn Biotec E2 USD | 751K | 0.88% | -19.38% | Jun 2026 |
| Candriam Eqs L Biotech C USD Cap | 553K | 0.65% | -2.88% | Apr 2026 |
| T. Rowe Price Health Sciences | 482K | 0.57% | -39.16% | Sep 2026 |
| abrdn Life Sciences Investors | 384K | 0.45% | 0.00% | Oct 2026 |
| Rhenman Healthcare Equity L/S RC2 SEK | 364K | 0.43% | 0.00% | Jan 2026 |
| JNL/T. Rowe Price Capital Appreciation A | 350K | 0.41% | 0.00% | Sep 2026 |
| BGF World Healthscience A2 | 338K | 0.40% | 0.00% | Jul 2026 |
| Candriam Eqs L Life Care V USD Acc | 231K | 0.27% | -6.95% | Apr 2026 |
| T. Rowe Price Capital Apprec Eq ETF | 215K | 0.25% | -0.55% | Oct 2026 |
| Belfius Equities Glob Health Care C$ Cap | 180K | 0.21% | -0.02% | Apr 2026 |
| GuideStone Funds Small Cap Equity Instl | 168K | 0.20% | +46.89% | Oct 2026 |
| MEDICAL BioHealth EUR Acc | 162K | 0.19% | +0.02% | Aug 2026 |
| BlackRock Health Sciences Opps Inv A | 161K | 0.19% | 0.00% | Sep 2026 |
| VY® T. Rowe Price Capital Apprec S | 160K | 0.19% | 0.00% | Sep 2026 |
| Fidelity Select Biotechnology | 144K | 0.17% | 0.00% | Aug 2026 |
| Vanguard Health Care ETF | 135K | 0.16% | +0.11% | Sep 2026 |
| Penn Series Fds Flexibly Managed | 112K | 0.13% | 0.00% | Sep 2026 |
| Nomura Healthcare Fund Class I | 110K | 0.13% | 0.00% | Sep 2026 |
Top institutions holding MLTX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Bvf Inc | 16.0M | 18.80% | 0.00% | Jun 2026 |
| Deep Track Capital, LP | 7.00M | 8.22% | +9.21% | Jun 2026 |
| T. Rowe Price Investment Management,Inc. | 4.28M | 5.03% | 0.00% | Jun 2026 |
| D. E. Shaw & Co LP | 3.37M | 3.95% | +40.78% | Jun 2026 |
| Cormorant Asset Management, LLC | 3.21M | 3.77% | -28.46% | Jun 2026 |
| Jupiter Topco LLC | 3.09M | 3.63% | 0.00% | Jun 2026 |
| Logos Global Management LP | 2.68M | 3.14% | +78.33% | Jun 2026 |
| Weiss Asset Management LP | 2.58M | 3.03% | +51.13% | Jun 2026 |
| Citadel Advisors Llc | 1.97M | 2.32% | +49.04% | Jun 2026 |
| Renaissance Technologies Corp | 1.72M | 2.02% | +167.01% | Sep 2026 |
| Two Sigma Investments LLC | 1.72M | 2.02% | +52.84% | Jun 2026 |
| MPM Oncology Impact Management LP | 1.61M | 1.89% | -11.27% | Jun 2026 |
| Vivo Capital, LLC | 1.40M | 1.65% | +40.00% | Jun 2026 |
| JPMorgan Chase & Co | 1.39M | 1.63% | +27.37% | Jun 2026 |
| Point72 Asset Management, L.P. | 1.16M | 1.36% | -15.33% | Jun 2026 |
| BlackRock Inc | 1.09M | 1.29% | +7.14% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 1.04M | 1.22% | -19.56% | Jun 2026 |
| Balyasny Asset Management LLC | 913K | 1.07% | -14.35% | Jun 2026 |
| Great Point Partners LLC | 856K | 1.01% | +71.16% | Jun 2026 |
| Jane Street Group LLC | 853K | 1.00% | +88.13% | Jun 2026 |
MoonLake Immunotherapeutics company profile
- Company name
- MoonLake Immunotherapeutics
- Ticker
- MLTX.US
- ISIN
- KY61559X1045
- Exchange
- USA Stocks
- Listed since
- Oct 20, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 130
- Fiscal year end
- December
- Address
- Dorfstrasse 29, Zug, Switzerland, 6300
- Phone
- 41 415108022
- Website
- moonlaketx.com
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
MoonLake Immunotherapeutics management
10- Dr. Jorge Santos da Silva Ph.D.Co-Founder, Interim Chair of the Board & CEO · born 1977
- Dr. Kristian Reich M.D., Ph.D.Co-Founder & Chief Scientific Officer · born 1966
- Mr. Matthias BodenstedtChief Financial Officer · born 1988
- Mr. Oliver Daltrop Ph.D.Chief Technical Officer
- Ms. Carla BretesDirector of Investor Relations & External Communications
- Mr. Nicolas Mosimann Ph.D.General Counsel
- Joana CortezAssociate Vice-President of Legal & Compliance
- Tino AnthamattenVice President of Marketing, Market Access & Pricing
- Luciana MarquesAssociate Vice-President of HR, People and Culture
- Ms. Nuala BrennanChief Clinical Development Officer